- Home
- CCIX vs ERAS Comparison
CCIX vs ERAS Comparison
Compare CCIX & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCIX
- ERAS
- Stock Information
- Founded
- CCIX 2023
- ERAS 2018
- Country
- CCIX United States
- ERAS United States
- Employees
- CCIX N/A
- ERAS N/A
- Industry
- CCIX
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- CCIX
- ERAS Health Care
- Exchange
- CCIX Nasdaq
- ERAS Nasdaq
- Market Cap
- CCIX 388.3M
- ERAS 348.4M
- IPO Year
- CCIX 2024
- ERAS 2021
- Fundamental
- Price
- CCIX $10.59
- ERAS $1.44
- Analyst Decision
- CCIX
- ERAS Strong Buy
- Analyst Count
- CCIX 0
- ERAS 6
- Target Price
- CCIX N/A
- ERAS $4.83
- AVG Volume (30 Days)
- CCIX 415.7K
- ERAS 1.3M
- Earning Date
- CCIX 01-01-0001
- ERAS 08-11-2025
- Dividend Yield
- CCIX N/A
- ERAS N/A
- EPS Growth
- CCIX N/A
- ERAS N/A
- EPS
- CCIX 0.34
- ERAS N/A
- Revenue
- CCIX N/A
- ERAS N/A
- Revenue This Year
- CCIX N/A
- ERAS N/A
- Revenue Next Year
- CCIX N/A
- ERAS N/A
- P/E Ratio
- CCIX $31.10
- ERAS N/A
- Revenue Growth
- CCIX N/A
- ERAS N/A
- 52 Week Low
- CCIX $10.00
- ERAS $1.01
- 52 Week High
- CCIX $11.66
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- CCIX N/A
- ERAS 52.55
- Support Level
- CCIX N/A
- ERAS $1.24
- Resistance Level
- CCIX N/A
- ERAS $1.51
- Average True Range (ATR)
- CCIX 0.00
- ERAS 0.12
- MACD
- CCIX 0.00
- ERAS -0.00
- Stochastic Oscillator
- CCIX 0.00
- ERAS 57.89
About CCIX Churchill Capital Corp IX Ordinary Shares
Churchill Capital Corp IX is a blank check company.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.